New paradigms for HIV/AIDS vaccine development

Annual Review of Medicine

Volumn 63, Issue , 2012, Pages 95-111

  Picker, Louis J ^a   Hansen, Scott G ^a   Lifson, Jeffrey D ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

Antibody vaccines; HIV SIV; Immune evasion; Nonhuman primate models; T cell vaccines

Indexed keywords

CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF PROTEIN; VIF PROTEIN; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR; VPU PROTEIN;

ADAPTIVE IMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOBIOLOGY; MEMORY T LYMPHOCYTE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; VACCINE FAILURE; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS VACCINES; ALLERGY AND IMMUNOLOGY; HUMANS;

EID: 84855913888     PISSN: 00664219     EISSN: 1545326X     Source Type: Book Series    
DOI: 10.1146/annurev-med-042010-085643     Document Type: Review

References (83)

1. Grovit-Ferbas K, Pappas T, O'Brien WA. 1999. Human immunodeficiency virus. In Persistent Viral Infections, ed. R Ahmed, AI Chen, pp. 3-45. Chichester, UK:Wiley
2. Cohen OJ, Fauci AS. 2001. Pathogenesis and medical aspects of HIV-1 infection. In Fields Virology, ed. DM Knipe, PM Howley, pp. 2043-94. Philadelphia: LippincottWilliams &Wilkins. 4th ed.
3. Hirsch VM, Lifson JD. 2000. Simian immunodeficiency virus infection of monkeys as a model system for the study of AIDS pathogenesis, treatment, and prevention. Adv. Pharmacol. 49:437-77
4. McMichael AJ, Borrow P, Tomaras GD, et al. 2010. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10:11-23
5. O'ConnorDH, Allen TM, VogelTU, et al. 2002. Acute phase cytotoxicTlymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. 8:493-99 (Pubitemid 34546752)
6. Hahn BH, Shaw GM, De Cock KM, et al. 2000. AIDS as a zoonosis: scientific and public health implications. Science 287:607-14 (Pubitemid 30070900)
7. Brenchley JM, Silvestri G, Douek DC. 2010. Nonprogressive and progressive primate immunodeficiency lentivirus infections. Immunity 32:737-42
8. Walker BD, Burton DR. 2008. Toward an AIDS vaccine. Science 320:760-64 (Pubitemid 351929619)
9. Kirchhoff F. 2010. Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 8:55-67
10. Burton DR, Stanfield RL, Wilson IA. 2005. Antibody versus HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. USA 102:14943-48 (Pubitemid 41513316)
11. Mascola JR, MontefioriD C. 2010. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28:413-44
12. Hoxie JA. 2010. Toward an antibody-based HIV-1 vaccine. Annu. Rev. Med. 61:135-52
13. Levy JA. 1993. Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57:183-289 (Pubitemid 23078442)
14. Kunkel EJ, Boisvert J, Murphy K, et al. 2002. Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am. J. Pathol. 160:347-55 (Pubitemid 34052295)
15. Simmons G, Reeves JD, Hibbitts S, et al. 2000. Co-receptor use by HIV and inhibition of HIV infection by chemokine receptor ligands. Immunol. Rev. 177:112-26
16. Grossman Z, Meier-Schellersheim M, Paul WE, et al. 2006. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat. Med. 12:289-95 (Pubitemid 43355074)
17. Grossman Z, Picker LJ. 2008. Pathogenic mechanisms in simian immunodeficiency virus infection. Curr. Opin. HIV AIDS 3:380-86 (Pubitemid 351521025)
18. Haase AT. 2011. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu. Rev. Med. 62:127-39
19. Chun TW, Engel D, Berrey MM, et al. 1998. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 95:8869-73 (Pubitemid 28350581)
20. Mattapallil JJ, Douek DC, Hill B, et al. 2005. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434:1093-97 (Pubitemid 40663481)
21. Picker LJ, Hagen SI, Lum R, et al. 2004. Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. J. Exp. Med. 200:1299-314 (Pubitemid 39552571)
22. Zeng M, Smith AJ, Wietgrefe SW, et al. 2011. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV-1 and SIV infections. J. Clin. Invest. 121:998-1008
23. Bailey J, Blankson JN, Wind-Rotolo M, et al. 2004. Mechanisms of HIV-1 escape from immune responses and antiretroviral drugs. Curr. Opin. Immunol. 16:470-76 (Pubitemid 38881675)
24. Boutwell CL, Rolland MM, Herbeck JT, et al. 2010. Viral evolution and escape during acute HIV-1 infection. J. Infect. Dis. 202(Suppl. 2):S309-14
25. Goulder PJ, Watkins DI. 2008. Impact ofMHCclass I diversity on immune control of immunodeficiency virus replication. Nat. Rev. Immunol. 8:619-30
26. Dinges WL, Richardt J, Friedrich D, et al. 2010. Virus-specific CD8+ T-cell responses better define HIV disease progression than HLA genotype. J. Virol. 84:4461-68
27. Martins MA, Wilson NA, Reed JS, et al. 2010. T-cell correlates of vaccine efficacy after a heterologous simian immunodeficiency virus challenge. J. Virol. 84:4352-65
28. Walker BD. 2007. Elite control of HIV infection: implications for vaccines and treatment. Top. HIVMed. 15:134-36
29. Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et al. 2009. The firstTcell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 206:1253-72
30. Douek DC, Roederer M, Koup RA. 2009. Emerging concepts in the immunopathogenesis of AID S. Annu. Rev. Med. 60:471-84
31. Wei X, Decker JM, Wang S, et al. 2003. Antibody neutralization and escape byHIV-1. Nature 422:307-12
32. Richman DD, Wrin T, Little SJ, et al. 2003. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100:4144-49 (Pubitemid 36418171)
33. Euler Z, van Gils MJ, Bunnik EM, et al. 2010. Cross-reactive neutralizing humoral immunity does not protect from HIV type 1 disease progression. J. Infect. Dis. 201:1045-53
34. Reynolds MR, Rakasz E, Skinner PJ, et al. 2005. CD8+ T-lymphocyte response to major immunodominant epitopes after vaginal exposure to simian immunodeficiency virus: too late and too little. J. Virol. 79:9228-35 (Pubitemid 40934834)
35. Watkins DI, Burton DR, Kallas EG, et al. 2008. Nonhuman primate models and the failure of theMerck HIV-1 vaccine in humans. Nat. Med. 14:617-21 (Pubitemid 351809543)
36. Wilson NA, Reed J, Napoe GS, et al. 2006. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J. Virol. 80:5875-85 (Pubitemid 43849165)
37. Rosati M, von Gegerfelt A, Roth P, et al. 2005. DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge. J. Virol. 79:8480-92 (Pubitemid 40853549)
38. Mattapallil JJ, Douek DC, Buckler-White A, et al. 2006. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J. Exp. Med. 203:1533-41 (Pubitemid 43877613)
39. Liu J, O'Brien KL, Lynch DM, et al. 2009. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:87-91
40. Horton H, Vogel TU, Carter DK, et al. 2002. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J. Virol. 76:7187-202 (Pubitemid 41246232)
41. Hel Z, Nacsa J, Tryniszewska E, et al. 2002. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre-and postchallenge CD4+ and CD8+ T cell responses. J. Immunol. 169:4778-87 (Pubitemid 35217140)
42. Hel Z, Tsai WP, Tryniszewska E, et al. 2006. Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes. J. Immunol. 176:85-96 (Pubitemid 43023252)
43. Engram JC, Dunham RM, Makedonas G, et al. 2009. Vaccine-induced, simian immunodeficiency virusspecific CD8+ T cells reduce virus replication but do not protect from simian immunodeficiency virus disease progression. J. Immunol. 183:706-17
44. Casimiro DR, Wang F, Schleif WA, et al. 2005. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization withDNAand recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79:15547-55 (Pubitemid 43032336)
45. Barouch DH, Liu J, Lynch DM, et al. 2009. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J. Virol. 83:9584-90
46. Valentine LE, Watkins DI. 2008. Relevance of studyingTcell responses in SIV-infected rhesusmacaques. Trends Microbiol. 16:605-11
47. McDermott AB, O'Connor DH, Fuenger S, et al. 2005. Cytotoxic T-lymphocyte escape does not always explain the transient control of simian immunodeficiency virus SIVmac239 viremia in adenovirus-boosted and DNA-primed Mamu-A01-positive rhesus macaques. J. Virol. 79:15556-66 (Pubitemid 43032337)
48. Letvin NL, Mascola JR, Sun Y, et al. 2006. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312:1530-33 (Pubitemid 43865893)
49. Hansen SG, Ford JC, Lewis MS, et al. 2011. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523-27
50. Letvin NL, Rao SS, Montefiori DC, et al. 2011. Immune and genetic correlates of vaccine protection against mucosal infection by SIV in monkeys. Sci. Transl. Med. 3:81ra36
51. Buchbinder SP, Mehrotra DV, Duerr A, et al. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-93
52. McElrath MJ, DeRosa SC, Moodie Z, et al. 2008. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:1894-905
53. Rolland M, Tovanabutra S, deCamp AC, et al. 2011. Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial. Nat. Med. 17:366-71
54. Gray G, Buchbinder S, Duerr A. 2010. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr. Opin. HIV AIDS 5:357-61
55. McElrath MJ. 2010. Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection. J. Infect. Dis. 202(Suppl 2):S323-26
56. Flynn NM, Forthal DN, Harro CD, et al. 2005. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191:654-65
57. Pitisuttithum P, Gilbert P, Gurwith M, et al. 2006. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194:1661-71 (Pubitemid 44901996)
58. McElrath MJ, Haynes BF. 2010. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33:542-54
59. Simek MD, Rida W, Priddy FH, et al. 2009. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83:7337-48
60. Parren PW, Marx PA, Hessell AJ, et al. 2001. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75:8340-47 (Pubitemid 32743706)
61. Hessell AJ, Poignard P, Hunter M, et al. 2009. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15:951-54
62. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-20
63. Florese RH, Demberg T, Xiao P, et al. 2009. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J. Immunol. 182:3718-27
64. Forthal DN, Landucci G, Phan TB, et al. 2005. Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J. Virol. 79:2042-49 (Pubitemid 40204561)
65. Asmal M, Sun Y, Lane S, et al. 2011. Antibody-dependent cell-mediated viral inhibition emerges after simian immunodeficiency virus SIVmac251 infection of rhesus monkeys coincident with gp140-binding antibodies and is effective against neutralization-resistant viruses. J. Virol. 85:5465-75
66. Hladik F, Hope TJ. 2009. HIV infection of the genital mucosa in women. Curr. HIV/AIDS Rep. 6:20-28
67. Tudor D, Derrien M, Diomede L, et al. 2009. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection: an IgA gene and functional analysis. Mucosal Immunol. 2:412-26
68. Bomsel M, Tudor D, Drillet AS, et al. 2011. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34:269-80
69. Ruprecht RM. 1999. Live attenuated AIDS viruses as vaccines: promise or peril? Immunol. Rev. 170:135-49 (Pubitemid 29490751)
70. Johnson RP, Desrosiers RC. 1998. Protective immunity induced by live attenuated simian immunodeficiency virus. Curr. Opin. Immunol. 10:436-43 (Pubitemid 28393827)
71. Koff WC, Johnson PR, Watkins DI, et al. 2006. HIV vaccine design: insights from live attenuated SIV vaccines. Nat. Immunol. 7:19-23 (Pubitemid 41823864)
72. Jia B, Ng SK, DeGottardi MQ, et al. 2009. Immunization with single-cycle SIV significantly reduces viral loads after an intravenous challenge with SIV(mac)239. PLoS Pathog. 5:e1000272
73. Genesca M, McChesney MB, Miller CJ. 2009. Antiviral CD8+ T cells in the genital tract control viral replication and delay progression to AIDS after vaginal SIV challenge in rhesus macaques immunized with virulence attenuated SHIV 89. 6. J. Intern. Med. 265:67-77
74. Schmitz JE, Johnson RP, McClure HM, et al. 2005. Effect of CD8+ lymphocyte depletion on virus containment after simian immunodeficiency virus SIVmac251 challenge of live attenuated SIVmac239delta3-vaccinated rhesus macaques. J. Virol. 79:8131-41 (Pubitemid 40853516)
75. Reynolds MR, Weiler AM, Weisgrau KL, et al. 2008. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J. Exp. Med. 205:2537-50
76. Gauduin MC, Yu Y, Barabasz A, et al. 2006. Induction of a virus-specific effector-memory CD4+ T cell response by attenuated SIV infection. J. Exp. Med. 203:2661-72 (Pubitemid 44833342)
77. Reynolds MR, Weiler AM, Piaskowski SM, et al. 2010. Macaques vaccinated with simian immunodeficiency virus SIVmac239Delta nef delay acquisition and control replication after repeated low-dose heterologous SIV challenge. J. Virol. 84:9190-99
78. Powers C, Fruh K. 2008. Rhesus CMV: an emerging animal model for human CM V. Med. Microbiol. Immunol. 197:109-15
79. Hansen SG, Vieville C, Whizin N, et al. 2009. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat. Med. 15:293-99
80. Hansen SG, Powers CJ, Richards R, et al. 2010. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science 328:102-6
81. Kim JH, Rerks-Ngarm S, Excler JL, et al. 2010. HIV vaccines: lessons learned and the way forward. Curr. Opin. HIV AIDS 5:428-34
82. Corey L, Nabel GJ, Dieffenbach C, et al. 2011. HIV-1 vaccines and adaptive trial designs. Sci. Transl. Med. 3:79ps13
83. Mohr CA, Arapovic J, Muhlbach H, et al. 2010. A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination. J. Virol. 84:7730-42